Latest News for: egfr

Edit

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer ...

St Albans Messenger 21 Mar 2025
Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib ....
Edit

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

PR Newswire 20 Mar 2025
... five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.30.
Edit

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to ...

The Daily Times 06 Mar 2025
The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities ... .
Edit

EGFR Inhibitors-Induced Skin Disorders Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | ...

GetNews 06 Mar 2025
The Key EGFR Inhibitors-Induced Skin Disorders Companies in the market include - Lutris Pharma, Hoth Therapeutics, TWi Biotechnology, Inc., and others ... Some of the key facts of the EGFR Inhibitors-Induced Skin Disorders Market Report..
Edit

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing ...

Nasdaq Globe Newswire 05 Mar 2025
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer ... .
Edit

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy (Purple Biotech Ltd)

Public Technologies 05 Mar 2025
) פרפל ביוטק בע"מ. PURPLE BIOTECH LTD. Corporation no. 520031238. Israel Securities Authority Tel Aviv Stock Exchange C002( Public) Reported via MAGNA. 05/03/2025. www.isa.gov.il www.tase.co.il Reference. 2025-02-014800. Immediate Report ... 06/08/2024.
Edit

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets (Form 6-K) (Purple Biotech Ltd)

Public Technologies 05 Mar 2025
Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets. NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer.
Edit

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

PR Newswire 05 Mar 2025
The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities.
  • 1
×